Skip to Main content Skip to Navigation
New interface
Journal articles

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.

Résumé : New therapeutic options are needed for patients with psoriasis. Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis. In this study, we aimed to compare two tofacitinib doses with high-dose etanercept or placebo in this patient population.
Complete list of metadata

https://hal.univ-brest.fr/hal-01558410
Contributor : Ghislaine Calvez Connect in order to contact the contributor
Submitted on : Friday, July 7, 2017 - 4:05:16 PM
Last modification on : Thursday, January 20, 2022 - 3:39:58 AM

Identifiers

  • HAL Id : hal-01558410, version 1
  • PUBMED : 26051365

Citation

Hervé Bachelez, Peter C M van de Kerkhof, Robert Strohal, Alexey Kubanov, Fernando Valenzuela, et al.. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.. The Lancet, 2015, 386 (9993), pp.552-61. ⟨hal-01558410⟩

Share

Metrics

Record views

38